🇺🇸 ropivacaine HCl. in United States

27 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 27

Most-reported reactions

1. Pain — 4 reports (14.81%)
2. Hypotension — 3 reports (11.11%)
3. Local Anaesthetic Systemic Toxicity — 3 reports (11.11%)
4. Myoclonus — 3 reports (11.11%)
5. Myositis — 3 reports (11.11%)
6. Neurotoxicity — 3 reports (11.11%)
7. Anaesthetic Complication — 2 reports (7.41%)
8. Anxiety — 2 reports (7.41%)
9. Bradycardia — 2 reports (7.41%)
10. Cauda Equina Syndrome — 2 reports (7.41%)

Source database →

Frequently asked questions

Is ropivacaine HCl. approved in United States?

ropivacaine HCl. does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for ropivacaine HCl. in United States?

Shanghai Hengrui Pharmaceutical Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.